Marshall Wace, LLP Sage Therapeutics, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $1.15 Million - $1.94 Million	108,439 New	108,439 $1.18 Million
Q3 2023 Nov 14, 2023	SELL	$16.75 - $48.98 $10.3 Million - $30.2 Million	-617,492 Reduced 77.33%	181,056 $3.73 Million
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $24.9 Million - $36.5 Million	-613,381 Reduced 43.44%	798,548 $37.5 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $17.9 Million - $22.3 Million	479,006 Added 51.34%	1,411,929 $59.2 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $2.25 Million - $3.04 Million	-69,737 Reduced 6.96%	932,923 $35.6 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $19.8 Million - $26.5 Million	-612,646 Reduced 37.93%	1,002,660 $39.3 Million
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $27 Million - $37.3 Million	981,273 Added 154.77%	1,615,306 $52.2 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $18.4 Million - $27.4 Million	599,646 Added 1743.82%	634,033 $21 Million
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $1.66 Million - $2.11 Million	-44,834 Reduced 56.59%	34,387 $1.46 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $3.19 Million - $4.54 Million	79,221 New	79,221 $3.51 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $293,621 - $402,134	-4,156 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $448,063 - $683,179	-7,671 Reduced 64.86%	4,156 $360,000
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $486,444 - $738,596	11,827 New	11,827 $723,000
Q2 2020 Aug 13, 2020	SELL	$25.95 - $43.15 $691,593 - $1.15 Million	-26,651 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $458,017 - $1.35 Million	17,515 Added 191.71%	26,651 $765,000
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $411,270 - $1.06 Million	6,834 Added 296.87%	9,136 $660,000
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $420,028 - $568,740	-2,994 Reduced 56.53%	2,302 $323,000
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $2.77 Million - $3.21 Million	-17,549 Reduced 76.82%	5,296 $970,000
Q1 2019 May 14, 2019	SELL	$89.33 - $163.65 $4.62 Million - $8.46 Million	-51,703 Reduced 69.36%	22,845 $3.63 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $604,061 - $1.03 Million	7,372 Added 10.97%	74,548 $7.14 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $3.15 Million - $3.86 Million	-22,814 Reduced 25.35%	67,176 $9.49 Million
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $14.2 Million - $17.8 Million	-101,407 Reduced 52.98%	89,990 $14.1 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $8.61 Million - $10.9 Million	56,609 Added 42.0%	191,397 $30.8 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $8.18 Million - $22.6 Million	134,788	134,788 $22.2 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account